연구동향 분석

REVIEW : Vitamin D and chronic kidney disease

( Chang Seong Kim ) ( Soo Wan Kim ) 2014년

논문상세정보
인용/피인용
' REVIEW : Vitamin D and chronic kidney disease' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • cardiovasculardiseases
  • chronic
  • mortality
  • renal insuffi ciency
  • vitamin d
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
772 0

0.0%

' REVIEW : Vitamin D and chronic kidney disease' 의 참고문헌

  • Which vitamin D derivative to prescribe for renal patients
    Drueke TB Curr Opin Nephrol Hypertens 14 : 343 ~ 349 - [2005]
  • Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD
    Agarwal R Clin J Am Soc Nephrol 4 : 1523 ~ 1528 - [2009]
  • Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial
    Thadhani R JAMA 307 : 674 ~ 684 - [2012]
  • Vitamin D supplementation and mortality risk in chronic kidney disease:a meta-analysis of 20 observational studies
    Zheng Z BMC Nephrol 14 : 199 ~ [2013]
  • Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies
    Pilz S Am J Kidney Dis 58 : 374 ~ 382 - [2011]
  • Vitamin D levels and patient outcome in chronic kidney disease
    Ravani P Kidney Int 75 : 88 ~ 95 - [2009]
  • Vitamin D in chronic kidney disease: new potential for intervention
    Mirkovic K Curr Drug Targets 12 : 42 ~ 53 - [2011]
  • Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation
    Andress DL Kidney Int 69 : 33 ~ 43 - [2006]
  • Vitamin D deficiency, inf lammation, and albuminuria in chronic kidney disease: complex interactions
    Isakova T J Ren Nutr 21 : 295 ~ 302 - [2011]
  • Vitamin D deficiency and risk of cardiovascular disease
    Wang TJ Circulation 117 : 503 ~ 511 - [2008]
  • Vitamin D deficiency
    Holick MF N Engl J Med 357 : 266 ~ 281 - [2007]
  • Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase
    Hewison M Mol Cell Endocrinol 215 : 31 ~ 38 - [2004]
  • Vitamin D
    Dusso AS Am J Physiol Renal Physiol 289 : F8 ~ F28 - [2005]
  • Uremic plasma contains factors inhibiting 1alpha-hydroxylase activity
    Hsu CH J Am Soc Nephrol 3 : 947 ~ 952 - [1992]
  • Update in vitamin D
    Adams JS J Clin Endocrinol Metab 95 : 471 ~ 478 - [2010]
  • Transcription factor-kappa B (NF-kappa B) and renal disease
    Guijarro C Kidney Int 59 : 415 ~ 424 - [2001]
  • Therapeutic role and potential mechanisms of active vitamin D in renal interstitial fibrosis
    Tan X J Steroid Biochem Mol Biol 103 : 491 ~ 496 - [2007]
  • The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus
    Tanaka Y Arch Biochem Biophys 154 : 566 ~ 574 - [1973]
  • Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial f ibrosis induced by unilateral ureteral obstruction
    Sato M J Clin Invest 112 : 1486 ~ 1494 - [2003]
  • Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients
    Kalantar-Zadeh K Kidney Int 70 : 771 ~ 780 [2006]
  • Suppression of renin-angiotensin gene expression in the kidney by paricalcitol
    Freundlich M Kidney Int 74 : 1394 ~ 1402 - [2008]
  • Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
    de Zeeuw D Lancet 376 : 1543 ~ 1551 [2010]
  • Role of mitochondria in paricalcitol-mediated cytoprotection during obstructive nephropathy
    Garcia IM Am J Physiol Renal Physiol 302 : F1595 ~ F1605 - [2012]
  • Resurrection of vitamin D deficiency and rickets
    Holick MF J Clin Invest 116 : 2062 ~ 2072 - [2006]
  • Resolved: EMT produces fibroblasts in the kidney
    Zeisberg M J Am Soc Nephrol 21 : 1247 ~ 1253 - [2010]
  • Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats
    Park JW Am J Physiol Renal Physiol 298 : F301 ~ F313 - [2010]
  • Renal function and cardiovascular risk in hypertensive patients
    Ruilope LM J Hypertens 23 : 1787 ~ 1788 - [2005]
  • Regulation of gp330/megalin expression by vitamins A and D
    Liu W Eur J Clin Invest 28 : 100 ~ 107 - [1998]
  • Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis
    Jiang M Oncogene 25 : 4056 ~ 4066 - [2006]
  • Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats
    Bae S Cardiovasc Res 91 : 632 ~ 639 - [2011]
  • Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey
    Coresh J Am J Kidney Dis 41 : 1 ~ 12 - [2003]
  • Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States
    LaClair RE Am J Kidney Dis 45 : 1026 ~ 1033 - [2005]
  • Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease
    Levin A Kidney Int 71 : 31 ~ 38 - [2007]
  • Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation
    Park JW Eur J Pharmacol 683 : 301 ~ 309 - [2012]
  • Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling
    Tan X J Am Soc Nephrol 19 : 1741 ~ 1752 - [2008]
  • Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy
    Tan X J Am Soc Nephrol 17 : 3382 ~ 3393 - [2006]
  • Paricalcitol attenuates cyclosporine-induced kidney injury in rats
    Park JW Kidney Int 77 : 1076 ~ 1085 - [2010]
  • Paricalcitol attenuates 4-hydroxy-2-hexenal-induced inf lammation and epithelial-mesenchymal transition in human renal proximal tubular epithelial cells
    Kim CS PLoS One 8 : e63186 ~ - [2013]
  • Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis
    Usatii M Kidney Int 72 : 1330 ~ 1335 - [2007]
  • Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial
    Liu LJ Am J Kidney Dis 59 : 67 ~ 74 - [2012]
  • Megalin knockout mice as an animal model of low molecular weight proteinuria
    Leheste JR Am J Pathol 155 : 1361 ~ 1370 - [1999]
  • Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population
    Shoji T Nephrol Dial Transplant 19 : 179 ~ 184 - [2004]
  • Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist
    Zhang Y Am J Physiol Renal Physiol 297 : F791 ~ F801 - [2009]
  • Klotho and the Aging Process
    Makoto Kuro-o The Korean Journal of Internal Medicine 26 (2) : 113 ~ 122 - [2011]
  • KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification
    National Kidney Foundation Am J Kidney Dis 39 (2Suppl 1) : S1 ~ S266 [2002]
  • KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
  • Identification of a vitamin D-responsive element in the 5’-flanking region of the rat 25-hydroxyvitamin D3 24-hydroxylase gene
    Ohyama Y J Biol Chem 269 : 10545 ~ 10550 - [1994]
  • FGF23 induces left ventricular hypertrophy
    Faul C J Clin Invest 121 : 4393 ~ 4408 - [2011]
  • FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis
    Shimada T J Bone Miner Res 19 : 429 ~ 435 - [2004]
  • FGF-23 in patients with end-stage renal disease on hemodialysis
    Imanishi Y Kidney Int 65 : 1943 ~ 1946 - [2004]
  • Expression prof iling conf irms the role of endocytic receptor megalin in renal vitamin D3 metabolism
    Hilpert J Kidney Int 62 : 1672 ~ 1681 - [2002]
  • Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes
    Bischoff-Ferrari HA Am J Clin Nutr 84 : 18 ~ 28 - [2006]
  • Established and Newly Proposed Mechanisms of Chronic Cyclosporine Nephropathy
    윤혜은 The Korean Journal of Internal Medicine 24 (2) : 81 ~ 92 [2009]
  • Ergocalciferol and cholecalciferol in CKD
    Nigwekar SU Am J Kidney Dis 60 : 139 ~ 156 - [2012]
  • Effects of highdose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease
    Alvarez JA Eur J Clin Nutr 67 : 264 ~ 269 - [2013]
  • Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats
    Panichi V Kidney Int 60 : 87 ~ 95 - [2001]
  • Effect of paricalcitol on left ventricular mass and function in CKD: the OPERA trial
    Wang AY J Am Soc Nephrol 25 : 175 ~ 186 - [2014]
  • Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats
    Schwarz U Kidney Int 53 : 1696 ~ 1705 - [1998]
  • Dietary and serum phosphorus regulate f ibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice
    Perwad F Endocrinology 146 : 5358 ~ 5364 - [2005]
  • Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease
    Dusso AS Kidney Int 79 : 715 ~ 729 - [2011]
  • Cordoba-Lanus E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy
    Sanchez-Nino MD Am J Physiol Renal Physiol 302 : F647 ~ F657 - [2012]
  • Comparison of chronic kidney disease prevalence examined by the chronic kidney disease epidemiology collaboration equation with that by the modification of diet in renal disease equation in Korean adult population
    Shin SY J Clin Lab Anal [2014]
  • Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes
    Deb DK Kidney Int 77 : 1000 ~ 1009 - [2010]
  • Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers
    Larsson T Kidney Int 64 : 2272 ~ 2279 - [2003]
  • Chronic kidney disease, hypovitaminosis D, and mortality in the United States
    Mehrotra R Kidney Int 76 : 977 ~ 983 - [2009]
  • Chronic kidney disease and mortality risk: a systematic review
    Tonelli M J Am Soc Nephrol 17 : 2034 ~ 2047 - [2006]
  • Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies
    Segerer S J Am Soc Nephrol 11 : 152 ~ 176 [2000]
  • Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study
    Melamed ML Kidney Int 70 : 351 ~ 357 - [2006]
  • Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis
    Okada H Curr Mol Med 5 : 467 ~ 474 - [2005]
  • CYP24A1 exacerbated activity during diabetes contributes to kidney tubular apoptosis via caspase-3 increased expression and activation
    Tourigny A PLoS One 7 : e48652 ~ - [2012]
  • CD44v3-v10 reduces the profibrotic effects of TGF-beta1 and attenuates tubular injury in the early stage of chronic obstructive nephropathy
    Rampanelli E Am J Physiol Renal Physiol 305 : F1445 ~ F1454 - [2013]
  • Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury
    He W J Am Soc Nephrol 22 : 90 ~ 103 - [2011]
  • Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD
    Urena-Torres P Am J Kidney Dis 58 : 544 ~ 553 - [2011]
  • Apoptosis and acute kidney injury
    Havasi A Kidney Int 80 : 29 ~ 40 - [2011]
  • Antiapoptotic Effect of Paricalcitol in Gentamicin-induced Kidney Injury
    서상헌 The Korean Journal of Physiology & Pharmacology 17 (5) : 435 ~ 440 [2013]
  • An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH)vitamin D3
    Nykjaer A Cell 96 : 507 ~ 515 - [1999]
  • Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    Eijkelkamp WB J Am Soc Nephrol 18 : 1540 ~ 1546 - [2007]
  • Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials
    Holtkamp FA Eur Heart J 32 : 1493 ~ 1499 - [2011]
  • Active vitamin D treatment for reduction of residual proteinuria: a systematic review
    de Borst MH J Am Soc Nephrol 24 : 1863 ~ 1871 [2013]
  • Activated injectable vitamin D and hemodialysis survival: a historical cohort study
    Teng M J Am Soc Nephrol 16 : 1115 ~ 1125 - [2005]
  • A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis
    Makibayashi K Am J Pathol 158 : 1733 ~ 1741 - [2001]
  • 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III)
    de Boer IH Am J Kidney Dis 50 : 69 ~ 77 [2007]
  • 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat
    Kuhlmann A Am J Physiol Renal Physiol 286 : F526 ~ F533 - [2004]
  • 1,25-Dihydroxyvitamin D(3)prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway
    Xiao H Am J Nephrol 30 : 34 ~ 43 - [2009]
  • 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system
    Li YC J Clin Invest 110 : 229 ~ 238 - [2002]
  • 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes
    Wu J J Clin Invest 97 : 1577 ~ 1588 - [1996]